Stocks · News reference
Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in the first quarter of 2027Long-acting monoclonal antibody TNX-4800 is a rapidly acting alternative to vaccination
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-18 AccNo: 0001493152-26-039000 Size: 197 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events
Read original at edgarTonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
Read original at benzingaData show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003 outbreakThree new models for investigating mpox infection and pathogenesis identifiedTonix is advancing TNX-801, a
Read original at benzinga